Cancer drug trials show modest benefit: drugs target liver, gastric, head and neck cancers.
Hampton
Tracy
T
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use; D000068818:Cetuximab; D017326:Clinical Trials, Phase III as Topic; D004338:Drug Combinations; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy; D009536:Niacinamide / Q000031:analogs & derivatives; D010094:Oxonic Acid; D010671:Phenylurea Compounds; D011725:Pyridines / Q000627:therapeutic use; D000077157:Sorafenib; D013274:Stomach Neoplasms / Q000188:drug therapy; D005641:Tegafur
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D004338:Drug Combinations; D010671:Phenylurea Compounds; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D009536:Niacinamide; D010094:Oxonic Acid; D000077157:Sorafenib; D000068818:Cetuximab